Clinical Efficacy and Safety of Human Mesenchymal Stem Cell Therapy for Degenerative Disc Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 2

Subgroup analysis.

Responder analyses	6 months	12 months	24 months	36 months	Overall effect
Pain responder
MIC in VAS	[1.10, 5.84],	[1.22, 6.36],	[0.93, 4.48],	[0.67, 3.34],	[1.43, 3.25],
CSC in VAS	[1.14, 5.90],	[1.31, 7.12],	[0.76, 4.16],	[0.71, 3.71],	[1.44, 3.31],
ODI responder
MIC in ODI	[0.95, 4.92],	[0.84, 4.15],	[0.93, 4.84],	[0.93, 4.84],	[1.37, 3.10],
CSC in ODI	[0.71, 3.58],	[0.82, 4.23],	[0.88, 4.47],	[1.17, 6.74],	[1.33, 3.05],